Piperidinyl Compounds Selective N-Type Calcium Channel Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel assays and compounds that can selectively block N-type calcium channels to treat disorders associated with excessive calcium ion influx, as existing methods are either ineffective or have side effects like hypotension due to non-selective blockade of L-type channels.
Innovation Solution
The development of piperidinyl compounds represented by Formula I, which act as selective N-type calcium channel blockers, and a high-throughput assay to identify such compounds for therapeutic use in treating conditions like pain, neurodegenerative disorders, and cardiovascular issues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective calcium channel blockers are used to block calcium channels, then calcium influx is reduced providing therapeutic benefit, but L-type channels are also blocked causing hypotension
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (Formula I and Formula II) that target N-type calcium channels selectively. The compounds contain specific functional groups including piperidinyl moieties, carbonyl groups, and aromatic rings positioned to interact preferentially with N-type channel binding sites while avoiding L-type channel interaction, thus providing localized therapeutic action at the N-type channel site without affecting L-type channels
Solution Approach 2:
The patent segments the calcium channel blocking function by creating compounds that specifically target N-type channels rather than blocking all calcium channel types. This segmentation allows selective inhibition of N-type channels involved in pain transmission and neuroprotection while leaving L-type channels in cardiac and vascular smooth muscle unaffected, avoiding hypotension
2Reliability
If existing calcium channel blockers are used, then pain and neurological disorders are treated, but selectivity for N-type channels over L-type channels is insufficient
Solution Approach 1:
The compounds in Formula I and Formula II exhibit local quality through their specific molecular architecture designed to fit N-type channel binding pockets. Key structural elements include the piperidinyl ring system, carbonyl groups at specific positions, and aromatic substituents that create precise steric and electronic complementarity with N-type channel residues, enabling selective binding without cross-reactivity with L-type channels
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as the substituents on the piperidinyl ring, the length and composition of linker chains, and the nature of aromatic groups to optimize selectivity. These parameter adjustments fine-tune the compounds' affinity for N-type versus L-type channels, achieving high selectivity ratios
Data Source
AI summary
The invention relates to piperidinyl compounds of Formula (I): or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R1-R3 and Z are defined as set forth in the specification. The invention is also directed to an assay useful for identifying such compounds as N-type calcium channel modulators or blockers. The invention is also directed to the compounds of Formula (I) and compounds identified by the above assay, and the use of such compounds to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.